Biodesix, Inc. (NASDAQ: BDSX) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $84M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Biodesix, Inc. had a Maz Rating of 4.50 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.90), among the strongest in its sector; its weakest was Financial Health (1.72), below most of its sector. The other factors: Growth 4.08 (above most of its sector); Profitability 3.37 (around the middle of its sector); Valuation 2.87 (valued in line with its sector). The current rating is for members: log in to see it.
At $10.34, Biodesix, Inc. trades at 0.8x sales and 12.9x book value. Over the last twelve months it generated about $104M of revenue and a net loss of $22M. It runs a gross margin of 63.9%, an operating margin of -18.7% and a net margin of -25.7%. It shows return on equity of -442.3%, return on invested capital of -24.0% and a free cash flow yield of -22.5%. On the balance sheet: a debt-to-equity ratio of 8.35 and a current ratio of 2.96. Over the past 52 weeks the share price ranged from $5.26 to $31.97, with a beta of 0.55.
Biodesix, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.